Q2 EPS Estimates for Veeva Systems Lifted by Zacks Research

Veeva Systems Inc. (NYSE:VEEV) – Stock analysts at Zacks Research increased their Q2 2026 earnings estimates for Veeva Systems in a research note issued to investors on Wednesday, March 26th. Zacks Research analyst R. Department now forecasts that the technology company will post earnings of $1.22 per share for the quarter, up from their prior forecast of $1.14. The consensus estimate for Veeva Systems’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Veeva Systems’ Q3 2026 earnings at $1.33 EPS, Q4 2026 earnings at $1.31 EPS, Q1 2027 earnings at $1.32 EPS and Q2 2027 earnings at $1.35 EPS.

Several other research analysts also recently commented on VEEV. Evercore ISI lifted their target price on Veeva Systems from $220.00 to $245.00 and gave the stock an “in-line” rating in a research note on Friday, December 6th. StockNews.com raised shares of Veeva Systems from a “hold” rating to a “buy” rating in a research report on Monday, February 17th. Citigroup raised their target price on shares of Veeva Systems from $281.00 to $307.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Scotiabank lifted their target price on shares of Veeva Systems from $240.00 to $245.00 and gave the stock a “sector perform” rating in a report on Thursday, March 6th. Finally, The Goldman Sachs Group cut shares of Veeva Systems from a “buy” rating to a “sell” rating and lowered their price target for the company from $261.00 to $200.00 in a report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $256.52.

Veeva Systems Trading Down 1.4 %

NYSE:VEEV opened at $234.10 on Friday. The stock has a market capitalization of $38.01 billion, a PE ratio of 57.80, a P/E/G ratio of 1.89 and a beta of 0.88. Veeva Systems has a 1-year low of $170.25 and a 1-year high of $258.93. The firm has a fifty day simple moving average of $231.62 and a 200 day simple moving average of $222.87.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Leigh Baldwin & CO. LLC purchased a new position in Veeva Systems in the 4th quarter worth approximately $685,355,000. Norges Bank bought a new position in Veeva Systems in the fourth quarter valued at $294,785,000. Principal Financial Group Inc. increased its stake in Veeva Systems by 138.9% in the third quarter. Principal Financial Group Inc. now owns 2,179,284 shares of the technology company’s stock valued at $457,366,000 after acquiring an additional 1,267,061 shares during the last quarter. JPMorgan Chase & Co. raised its position in Veeva Systems by 73.2% during the third quarter. JPMorgan Chase & Co. now owns 2,558,592 shares of the technology company’s stock valued at $536,972,000 after purchasing an additional 1,081,501 shares in the last quarter. Finally, Wealthfront Advisers LLC lifted its stake in Veeva Systems by 29,760.5% during the fourth quarter. Wealthfront Advisers LLC now owns 1,048,700 shares of the technology company’s stock worth $220,489,000 after purchasing an additional 1,045,188 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.